Scarica l'app Stockscreener
55.46
8.86%
-5.35
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Precedente Chiudi:
$60.81
Aprire:
$60.7
Volume 24 ore:
1.81M
Relative Volume:
0.89
Capitalizzazione di mercato:
$5.29B
Reddito:
$170.10M
Utile/perdita netta:
$-239.59M
Rapporto P/E:
-19.81
EPS:
-2.8
Flusso di cassa netto:
$-191.20M
1 W Prestazione:
+3.57%
1M Prestazione:
-1.84%
6M Prestazione:
-18.67%
1 anno Prestazione:
+25.30%
Intervallo 1D:
$55.05
$60.70
Intervallo di 1 settimana:
$51.00
$60.86
Portata 52W:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Nome
Crispr Therapeutics Ag
Settore
Industria
Telefono
(617) 315-4600
Indirizzo
BAARERSTRASSE 14, ZUG
Confronta CRSP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
55.46 | 5.80B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.14 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.58 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
818.35 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.51 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.10 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Iniziato | JP Morgan | Overweight |
| 2025-02-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Aggiornamento | TD Cowen | Sell → Hold |
| 2025-02-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-08-02 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-28 | Ripresa | Guggenheim | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-11 | Downgrade | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Iniziato | Mizuho | Buy |
| 2023-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-04-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2023-03-07 | Iniziato | Robert W. Baird | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-08-09 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-04-21 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-10 | Reiterato | Chardan Capital Markets | Buy |
| 2020-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-10 | Reiterato | Needham | Buy |
| 2020-12-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-07-28 | Reiterato | Needham | Buy |
| 2020-07-14 | Iniziato | SunTrust | Buy |
| 2020-06-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Iniziato | Jefferies | Buy |
| 2019-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-10 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-14 | Iniziato | William Blair | Mkt Perform |
| 2019-01-28 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-22 | Downgrade | Citigroup | Neutral → Sell |
Mostra tutto
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 5.8% on Insider Selling - MarketBeat
Retail Surge: Why is CRISPR Therapeutics AG stock going down2025 Short Interest & Consistent Profit Trading Strategies - mfd.ru
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $89.00 by Analysts at Bank of America - MarketBeat
CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing - TechStock²
CRISPR Therapeutics (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 30,000 Shares of Stock - MarketBeat
Samarth Kulkarni Sells 60,000 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat
Casgevy Revenue Surge and Clinical Advancements Bolster CRISPR Therapeutics’ Market Position - StocksToTrade
Why Crispr Therapeutics Stock Is Climbing Again - TipRanks
BofA Securities Adjusts Price Target on CRISPR Therapeutics AG to $89 From $90, Maintains Buy Rating - marketscreener.com
Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends - GlobeNewswire Inc.
Understanding Momentum Shifts in (CRSP) - Stock Traders Daily
Can CRISPR Therapeutics AG reach all time highs this yearJuly 2025 Patterns & Reliable Intraday Trade Alerts - baoquankhu1.vn
CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading - MSN
Investors heavily search CRISPR Therapeutics AG (CRSP): Here is what you need to know - MSN
Is It Time To Reassess CRISPR Therapeutics (CRSP) After Recent Gene Editing Progress? - Sahm
Meme Stocks: Will CRISPR Therapeutics AG benefit from geopolitical trendsJuly 2025 Selloffs & AI Powered Market Entry Ideas - baoquankhu1.vn
Price Action: Is CRISPR Therapeutics AG showing insider buyingJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Radnet (RDNT) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Nwam LLC Purchases 83,454 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Crispr Therapeutics AG (CRSP) Gets a Buy from Bank of America Securities - The Globe and Mail
How CRISPR Therapeutics’ Expanding Gene-Editing Pipeline and CTX310 Trial Progress Will Impact CRSP Investors - Sahm
CRISPR Therapeutics (CRSP) is considered a good investment by brokers: Is that true? - MSN
CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Aug Summary: Can CRISPR Therapeutics AG maintain its current growth rateEarnings Risk Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
A Look At CRISPR Therapeutics (CRSP) Valuation As 2026 Gene Editing Milestones Come Into Focus - Sahm
Is CRISPR Therapeutics (CRSP) Using J.P. Morgan Spotlight to Recast Its Gene-Editing Leadership Story? - Sahm
CRISPR Therapeutics: Patience And Opportunity Through Volatility (NASDAQ:CRSP) - Seeking Alpha
Sumitomo Mitsui Trust Group Inc. Sells 251,163 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - sharewise.com
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and NeoGenomics (NEO) - The Globe and Mail
What's Driving the Market Sentiment Around CRISPR Therapeutics AG? - Benzinga
CRSP: Casgevy and next-gen gene editing platforms drive growth, with 2026 set as a pivotal year - TradingView — Track All Markets
2 Biotech Stocks That Could Soar This Year - Finviz
CRISPR Therapeutics (CRSP) Is Considered a Good Investment by Brokers: Is That True? - Finviz
CRSP: Regulatory Submissions for CASGEVY Expected by Mid-2026 - GuruFocus
CRSP Outlines Strategic Goals and Milestones for 2026 - GuruFocus
CRISPR Therapeutics Highlights Pipeline Advances in Gene-Edited Therapies - TipRanks
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones - The Manila Times
CRISPR Therapeutics Outlines Strategic Priorities and Anticipated Milestones for 2026 - Quiver Quantitative
CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next - TechStock²
CRISPR Therapeutics Reports Q3 2025 Financial Results - MSN
Avoiding Lag: Real-Time Signals in (CRSP) Movement - Stock Traders Daily
Is CRISPR Therapeutics (CRSP) Attractive After Recent Gene Editing Progress And Mixed Returns? - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - sharewise.com
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next - TechStock²
Revenue Check: How CRISPR Therapeutics AG stock valuations compare to rivalsStop Loss & Detailed Earnings Play Strategies - moha.gov.vn
Quarterly Risk: Is CRISPR Therapeutics AG stock a contrarian buyJuly 2025 Setups & Community Verified Watchlist Alerts - ulpravda.ru
Can CRISPR Therapeutics AG stock beat market expectations this quarterTreasury Yields & Real-Time Market Sentiment Reports - ulpravda.ru
Why global investors buy CRISPR Therapeutics AG (1CG) stock2025 Technical Patterns & Real-Time Market Sentiment Reports - ulpravda.ru
CRISPR Therapeutics AG CFO Sells Shares Under Trading Plan - TradingView — Track All Markets
Institutional Investors Are CRISPR Therapeutics AG's (NASDAQ:CRSP) Biggest Bettors and Were Rewarded After Last Week's US$529m Market Cap Gain - 富途牛牛
Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.67%
2.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):